What Does 21 CFR Part 11 Actually Require?

21 CFR Part 11 is an FDA regulation that establishes the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures.

The regulation was introduced as organizations began moving away from paper-based processes and toward digital systems. FDA needed assurance that records created, stored, modified, and approved electronically would maintain the same level of integrity and accountability as traditional paper records.

Simply put, if your organization uses electronic systems to manage regulated records, Part 11 may apply.

Many organizations approach Part 11 as a checklist exercise. However, FDA inspections today are increasingly focused on a broader question:

When inspectors evaluate computerized systems, they are typically looking for evidence that records are:

• Accurate
• Complete
• Consistently maintained
• Secure from unauthorized changes
• Readily available for review

This aligns closely with FDA's continued emphasis on data integrity principles throughout the life sciences industry.

One of the most important elements of Part 11 is the ability to reconstruct the history of a record.

Organizations must be able to demonstrate

• Who performed an action
• What action was performed
• When the action occurred
• Whether changes were made to a record

These audit trails should be computer generated and preserved as part of the record history.

During inspections, auditors frequently review audit trail functionality because it provides visibility into how records have been managed over time.

Without a reliable audit trail, it becomes difficult to establish confidence in the integrity of regulated data.

Electronic signatures are often the most visible aspect of Part 11 compliance.

However, an electronic signature is much more than a digital approval button.

FDA expects electronic signatures to be uniquely linked to an individual and permanently associated with the corresponding record.

Organizations should be able to demonstrate:

• The identity of the signer
• The date and time of signing
• The purpose of the signature
• Protection against unauthorized use

Whether a signature represents review, approval, authorization, or verification, it must provide a clear and attributable record of accountability.

Not every employee should have the same level of access to regulated records.

Part 11 requires organizations to establish controls that restrict access to authorized individuals.

This often includes:

• User authentication
• Password management
• Role based permissions
• Controlled administrative privileges

Effective access controls help prevent unauthorized modifications and reduce the risk of data integrity issues.

Inspectors frequently review how organizations manage user accounts, permissions, and system access as part of computerized system assessments.

Electronic records must remain accessible throughout their required retention period.

Organizations should be able to retrieve records quickly and accurately during:

• FDA inspections
• Internal audits
• Customer audits
• Regulatory reviews

A record that cannot be located when requested may be viewed similarly to a record that does not exist.

For this reason, document management and record retention strategies play a critical role in maintaining compliance.

System validation remains one of the most misunderstood requirements associated with Part 11.

FDA expects organizations to demonstrate that computerized systems consistently perform as intended.

Validation activities typically include:

• Defining system requirements
• Assessing risks
• Conducting testing
• Documenting results
• Managing system changes

The goal is not simply to generate validation documentation. The goal is to establish confidence that the system reliably supports regulated processes and maintains data integrity.

Modern FDA expectations increasingly emphasize a risk based approach to validation, focusing effort where system failures could have the greatest impact on product quality, patient safety, or data reliability.

Part 11 only applies to pharmaceutical manufacturers.

False. The regulation can apply across a wide range of regulated life sciences organizations, including biotechnology companies, medical device manufacturers, laboratories, contract research organizations, and contract manufacturing organizations.

If a vendor says their software is Part 11 compliant, we are compliant.

Not necessarily. Software can provide the technical capabilities needed to support compliance, but organizations remain responsible for how systems are configured, validated, managed, and used.

Compliance is ultimately a combination of technology, processes, procedures, and user behavior.

Electronic signatures are the only requirement.

Electronic signatures are only one component of Part 11. Audit trails, access controls, validation, record retention, and data integrity controls are equally important

Despite widespread digital adoption, many regulated organizations continue to operate with disconnected systems and manual processes.

Documents may reside in multiple repositories. Approvals may occur through email. Training records may be maintained separately from quality documentation. Audit trails may be difficult to review or incomplete.

These fragmented processes create challenges during inspections because demonstrating traceability often requires gathering information from multiple sources.

As regulatory scrutiny around data integrity continues to increase, organizations are placing greater emphasis on centralized and controlled digital environments that support compliance throughout the record lifecycle.

The conversation around Part 11 is no longer just about replacing paper.

Today, the focus is on creating reliable digital processes that support data integrity, operational efficiency, and inspection readiness.

Organizations that succeed in this environment typically prioritize:

• Controlled document management
• Secure electronic signatures
• Automated audit trails
• Risk based validation
• Centralized record management
• Strong access controls
• Consistent quality processes

When these elements work together, compliance becomes a natural outcome of daily operations rather than a last-minute effort before an audit.